{"classes":[{"categories":[{"measurements":[{"comment":"Insufficient number of participants with events to estimate median and upper 95% confidence limit.","groupId":"OG000","lowerLimit":"31.3","upperLimit":"NA","value":"NA"},{"groupId":"OG001","lowerLimit":"32.2","upperLimit":"41.4","value":"33.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"282"},{"groupId":"OG001","value":"246"}],"units":"Participants"}],"description":"DOR is defined as the time from the date that response criteria were first met to the date that disease progression was objectively documented or death, whichever occurred first, determined by independent central review. Median DOR was estimated using the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 160 mg zanubrutinib orally twice daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy.","id":"OG000","title":"Zanubrutinib"},{"description":"Participants received ibrutinib 420 mg orally once daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy.","id":"OG001","title":"Ibrutinib"}],"paramType":"MEDIAN","populationDescription":"Participants in the ITT Analysis Set with an objective response assessed by the IRC","reportingStatus":"POSTED","timeFrame":"From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).","title":"Duration of Response Assessed by the Independent Review Committee","type":"SECONDARY","unitOfMeasure":"months"}